US 10,292,965 B2 · Nintedanib diethanesulfonate salt crystal and preparation method and use thereof

Abstract

The present invention relates to a nintedanib diethanesulfonate salt A-type crystal represented by formula (II), and also relates to a crystalline composition and pharmaceutical composition comprising the crystal, and preparation method and use thereof. An X-ray powder diffraction spectrum of the nintedanib diethanesulfonate salt A-type crystal of the present invention has a diffraction peak at about 14.64, 18.79, 19.31, 20.11, 21.20, 22.45 and 26.71° when represented via a 2θ value. The nintedanib diethanesulfonate salt A-type crystal of the present invention has a stable property, is non-hygroscopic and difficult to degrade, and is particularly suitable for medicine production.

Claims19

Dependent claims

A crystalline Form A of nintedanib diethanesulfonate represented by Formula (II),

wherein the X-ray powder diffraction spectrum of the crystalline Form A has diffraction peaks expressed by 2θ values at about 14.64, 18.79, 19.31, 20.11, 21.20, 22.45 and 26.71 degrees.

Dependencies are inferred from the claim text.

Facts

Application

15/558,050Filed 11 Mar 2016

Priority

CN 2015 1 011290913 Mar 2015

Published

US 2018/0064684 A18 Mar 2018

Granted

21 May 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification13 codes

A61K 31/404
Condensed with carbocyclic rings, e.g. carbazole: indoles, e.g. pindolol
A61K 31/496
Having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines: non-condensed piperazines…
A61P 11/00
Drugs for disorders of the respiratory system
A61P 35/00
Antineoplastic agents

Nintedanib diethanesulfonate salt crystal and preparation method and use thereof

Life of this patent

Nintedanib diethanesulfonate salt crystal and preparation method and use thereof

Life of this patent

Abstract

Claims19